Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

NASDAQ:LEGN

Legend Biotech

Last Close

45.93

03/05 20:00

Market Cap

8.26B

Beta: −0.08

Volume Today

679.86K

Avg: 810.09K

PE Ratio

−39.80

PFCF: −29.36

locale

market

industry

website

crunchbase

ipo date

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics